Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Boji Medical and Great Bay Bio Form JV for Long-Acting Anemia Biologic

publication date: Oct 18, 2019

Guangzhou Boji Medical Biotech, a CRO, formed a JV with Great Bay Bio of Hong Kong to develop GBB101, a novel long-acting injectable biologic designed to treat anemia caused by chronic kidney disease. Great Bay is an AI-based CMC CDMO focused on innovative biologics. The two companies, which expect GBB101 to be one of the first long-acting anti-anemia products from a China biopharma, will each invest capital in the JV, though details were not provided. More details....

Stock Symbols: (SHE: 300404)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here